Beta Bionics (NASDAQ:BBNX) Insider Sells 30,779 Shares of Stock

Beta Bionics, Inc. (NASDAQ:BBNX) insider Mark Hopman sold 30,779 shares of the company’s stock in a transaction that occurred on Wednesday, September 16th. The shares were sold at an average price of $20.13, for a total transaction of $619,581.27. Following the completion of the sale, the insider owned 56,479 shares of the company’s stock, valued at approximately $1,136,922.27. This trade represents a 35.27% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Mark Hopman also recently made the following trade(s):

• On Wednesday, September 9th, Mark Hopman sold 36,870 shares of Beta Bionics stock. The shares were sold at an average price of $18.46, for a total value of $680,620.20.
• On Wednesday, September 2nd, Mark Hopman sold 5,327 shares of Beta Bionics stock. The stock was sold at an average price of $19.11, for a total transaction of $101,798.97.
• On Wednesday, June 24th, Mark Hopman sold 1,258 shares of Beta Bionics stock. The stock was sold at an average price of $15.01, for a total transaction of $18,882.58.

Beta Bionics Price Performance

BBNX traded down $0.75 on Thursday, reaching $21.43. 3,089,176 shares of the company traded hands, compared to its average volume of 1,193,079. The company has a market cap of $964.14 million, a price-to-earnings ratio of -12.99 and a beta of 3.37. The stock’s 50 day moving average price is $17.46 and its 200-day moving average price is $13.93. Beta Bionics, Inc. has a 52-week low of $8.80 and a 52-week high of $32.71.

Beta Bionics (NASDAQ:BBNX) last issued its earnings results on Wednesday, July 29th. The company reported ($0.53) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.62) by $0.09. Beta Bionics had a negative net margin of 61.31% and a negative return on equity of 26.30%. The company had revenue of $32.01 million during the quarter. As a group, equities research analysts forecast that Beta Bionics, Inc. will post -2.05 earnings per share for the current fiscal year.

Trending Headlines about Beta Bionics

Here are the key news stories impacting Beta Bionics this week:

• Positive Sentiment: The U.S. FDA cleared Beta Bionics’ Mint patch pump, expanding the company’s diabetes-device portfolio beyond the iLet Bionic Pancreas. A full U.S. launch is planned for the first quarter of 2027, creating a potential additional growth driver. Beta Bionics Stock Surges on FDA Clearance for Mint Patch Pump
• Positive Sentiment: Analysts and market coverage have highlighted the Mint clearance as a step toward a broader, multi-product growth strategy. Recent earnings-estimate trends and a price-target increase from Bank of America also supported buying interest. Beta Bionics Shares Rise After BofA Price-Target Boost
• Positive Sentiment: Beta Bionics priced a public offering expected to raise approximately $150 million. The proceeds could fund Mint commercialization, manufacturing expansion, research and development, and working capital, improving financial flexibility. Beta Bionics Announces Pricing of Public Offering
• Neutral Sentiment: The offering includes 7.65 million common shares and pre-funded warrants for approximately 1.04 million additional shares, with a potential underwriters’ option for 1.30 million more shares. The capital raise strengthens the balance sheet but increases the potential share count.
• Negative Sentiment: Multiple law firms are publicizing a securities class action against Beta Bionics. The litigation alleges that management understated the significance of FDA Form 483 findings, a subsequent warning letter, quality-management issues, and unreported customer complaints. Investors have until November 3, 2026, to seek lead-plaintiff status; the allegations have not been proven. BBNX Shareholder Alert
• Negative Sentiment: Beta Bionics’ updated 2026 revenue outlook of $121 million to $126 million is below the roughly $133.9 million consensus estimate, raising concerns about near-term execution and commercialization. The equity offering may also weigh on the stock through dilution.

Hedge Funds Weigh In On Beta Bionics

Several institutional investors have recently bought and sold shares of the stock. BlackRock Inc. acquired a new stake in shares of Beta Bionics in the second quarter worth about $52,340,000. Healthcare of Ontario Pension Plan Trust Fund bought a new stake in shares of Beta Bionics during the 4th quarter worth about $40,437,000. Eversept Partners LP increased its holdings in shares of Beta Bionics by 108.6% during the 1st quarter. Eversept Partners LP now owns 1,414,838 shares of the company’s stock valued at $14,177,000 after acquiring an additional 736,576 shares during the last quarter. 12 West Capital Management LP acquired a new position in shares of Beta Bionics during the 4th quarter valued at about $17,520,000. Finally, Bruce & Co. Inc. bought a new position in shares of Beta Bionics in the 1st quarter valued at approximately $5,518,000.

Analyst Ratings Changes

BBNX has been the subject of a number of recent research reports. Truist Financial reaffirmed a “buy” rating and set a $23.00 price target (up from $22.00) on shares of Beta Bionics in a research note on Tuesday. Bank of America boosted their price target on Beta Bionics from $18.00 to $20.00 and gave the company a “neutral” rating in a research note on Tuesday. UBS Group restated a “buy” rating and issued a $25.00 price objective on shares of Beta Bionics in a report on Tuesday. Leerink Partners raised their price objective on shares of Beta Bionics from $24.00 to $27.00 and gave the company an “outperform” rating in a research report on Monday. Finally, The Goldman Sachs Group lifted their target price on shares of Beta Bionics from $17.00 to $19.00 and gave the company a “buy” rating in a research note on Wednesday, July 15th. Seven analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $21.90.

About Beta Bionics

Beta Bionics, Inc is a medical technology company focused on developing automated insulin-delivery systems for people with diabetes. Its principal product is the iLet Bionic Pancreas, an automated insulin-delivery system designed to simplify diabetes management by using continuous glucose monitoring data to adjust insulin dosing with limited user input.

The iLet Bionic Pancreas received clearance from the U.S. Food and Drug Administration in 2023 for use by people with type 1 diabetes.